Statera Biopharma (STAB) Competitors

$0.0006

0.00 (0.00%)

(As of 07/26/2024 ET)

Stock Analysis Chart Competitors Financials Headlines SEC Filings Trends

STAB vs. CALA, SCPS, LSDI, EVLO, AMPE, ONCSQ, AEHAW, SUBL, GRFS, and LVTX

Should you be buying Statera Biopharma stock or one of its competitors? The main competitors of Statera Biopharma include Calithera Biosciences (CALA), Scopus BioPharma (SCPS), Lucy Scientific Discovery (LSDI), Evelo Biosciences (EVLO), Ampio Pharmaceuticals (AMPE), OncoSec Medical (ONCSQ), Aesther Healthcare Acquisition (AEHAW), BioLingus (Cayman) (SUBL), Grifols (GRFS), and LAVA Therapeutics (LVTX).

Statera Biopharma vs.

Calithera Biosciences (NASDAQ:CALA) and Statera Biopharma (NASDAQ:STAB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment, valuation and community ranking.

: In the previous week, Statera Biopharma's average media sentiment score of 0.00 equaled Calithera Biosciences'average media sentiment score.
Company Overall Sentiment
Calithera Biosciences Neutral
Statera Biopharma Neutral
: Company Net Margins Return on Equity Return on Assets
Calithera Biosciences N/A N/A N/A
Statera Biopharma N/A N/A N/A
: Calithera Biosciences has higher revenue and earnings than Statera Biopharma.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Calithera Biosciences $9.75M 0.01 -$39.65M N/A N/A
Statera Biopharma $1.49M 0.02 -$101.85M N/A N/A
: Calithera Biosciences has a beta of -0.18, meaning that its share price is 118% less volatile than the S&P 500. Comparatively, Statera Biopharma has a beta of 0.44, meaning that its share price is 56% less volatile than the S&P 500.
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Calithera Biosciences
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
Statera Biopharma
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
: Calithera Biosciences received 341 more outperform votes than Statera Biopharma when rated by MarketBeat users.
Company Underperform Outperform
Calithera Biosciences Outperform Votes
341
58.69%
Underperform Votes
240
41.31%
Statera Biopharma N/A N/A

Company	Overall Sentiment
Calithera Biosciences	Neutral
Statera Biopharma	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Calithera Biosciences	N/A	N/A	N/A
Statera Biopharma	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calithera Biosciences	$9.75M	0.01	-$39.65M	N/A	N/A
Statera Biopharma	$1.49M	0.02	-$101.85M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calithera Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Statera Biopharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Company	Underperform	Outperform
Calithera Biosciences	Outperform Votes 341 58.69%	Underperform Votes 240 41.31%
Statera Biopharma	N/A	N/A

Summary

Calithera Biosciences beats Statera Biopharma on 3 of the 5 factors compared between the two stocks.

Ad Unstoppable Prosperity

“Generational Bull Run” Incoming

LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.

You can find out what they are by clicking here now.

Get Statera Biopharma News Delivered to You Automatically

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STAB vs. The Competition

Export to Excel

Metric	Statera Biopharma	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$33,000.00	$7.07B	$5.27B	$8.22B
Dividend Yield	N/A	2.81%	2.79%	3.96%
P/E Ratio	N/A	14.36	148.37	16.86
Price / Sales	0.02	288.63	2,041.47	82.52
Price / Cash	N/A	32.58	35.42	34.13
Price / Book	N/A	5.89	4.94	4.51
Net Income	-$101.85M	$147.89M	$111.35M	$216.46M
7 Day Performance	N/A	2.92%	2.70%	1.75%
1 Month Performance	N/A	10.25%	11.35%	7.84%
1 Year Performance	N/A	2.06%	9.87%	3.01%

Statera Biopharma Competitors List

Export to Excel

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CALA Calithera Biosciences	0 of 5 stars 0.00 / 5 stars	$0.01 -44.4%	N/A	-16.7%	$61,000.00	$9.75M	0.00	8	Gap Down
SCPS Scopus BioPharma	0 of 5 stars 0.00 / 5 stars	N/A	N/A	N/A	$8,000.00	N/A	0.00	13
LSDI Lucy Scientific Discovery	0 of 5 stars 0.00 / 5 stars	$0.00 flat	N/A	-100.0%	$4,000.00	$16,732.00	0.00	2	Gap Up
EVLO Evelo Biosciences	0 of 5 stars 0.00 / 5 stars	N/A	N/A	-100.0%	$2,000.00	N/A	0.00	120	Options Volume News Coverage High Trading Volume
AMPE Ampio Pharmaceuticals	0 of 5 stars 0.00 / 5 stars	$0.00 flat	N/A	-100.0%	$1,000.00	N/A	0.00	20	Analyst Forecast
ONCSQ OncoSec Medical	0 of 5 stars 0.00 / 5 stars	N/A	N/A	N/A	$1,000.00	N/A	0.00	40
AEHAW Aesther Healthcare Acquisition	0 of 5 stars 0.00 / 5 stars	$0.04 flat	N/A	-80.9%	$0.00	N/A	0.00	2	Gap Down
SUBL BioLingus (Cayman)	0 of 5 stars 0.00 / 5 stars	N/A	N/A	N/A	$0.00	N/A	0.00	N/A	High Trading Volume
GRFS Grifols	2.7496 of 5 stars 2.75 / 5 stars	$7.78 +0.6%	$10.50 +35.0%	-21.1%	$0.00	$7.13B	0.00	23,737	Short Interest ↓
LVTX LAVA Therapeutics	2.6683 of 5 stars 2.67 / 5 stars	$2.11 +6.6%	$6.00 +184.4%	+10.5%	$0.00	$6.77M	-1.95	37	Short Interest ↓